Thank you @MoonBuggy for the informative literature into both the medications we are trialing. The scope and the target market is enormous and they address some critical issues.
From the financial standpoint, this morning’s announcement on FullyFunded manufacturing shows a commitment from both the company and our funding partner Clendon. This is more evidence on the credibility of Clendon.
With all trial aspects of funding sorted, the cash requirements for the administrative parts of the company seems pretty low from past years’ accounts. I believe any cash raise will be kept low.
GLTA holders.
IRX 616a World 1st Fast Acting Non Addictive Anxiety Solution, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.964M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | 3.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 330000 | 1 |
View Market Depth
| Last trade - 16.00pm 17/07/2025 (20 minute delay) ? |
| IRX (ASX) Chart |
Day chart unavailable